Bydureon (exenatide XR once-weekly) / AstraZeneca - LARVOL DELTA

Body Composition and Lifestyle Interventions in Pharmacological Treatment of Acquired Hypothalamic Obesity: A Systematic Review of Randomized Controlled Trials. (PubMed, Obesity (Silver Spring)) - "Current evidence suggests that selected pharmacological interventions may improve weight-related and body composition outcomes in aHO; however, evidence remains limited and of predominantly low certainty. Existing studies are constrained by inadequate assessment of lean body mass and poorly standardized lifestyle interventions. Future large-scale, long-term RCTs incorporating systematic body composition assessment and structured lifestyle intervention protocols are needed."

Journal • Review • Genetic Disorders • Hypothalamic Injury-associated Obesity • Obesity

Meal Replacement Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease in Adolescents with Severe Obesity. (PubMed, Child Obes) - P2 | "Short-term MRT was associated with reductions in liver fat and improvements in metabolic biomarkers among adolescents with MASLD. Large-scale trials are needed to evaluate the implementation of MRT as part of a multimodal treatment strategy in this population. [Clinical Trial Registration: Enhancing Weight Loss Maintenance with GLP-1 RA (BYDUREON™) in Adolescents With Severe Obesity, NCT02496611, https://clinicaltrials.gov/study/NCT02496611]."

Journal • Genetic Disorders • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • LEP

GAP-SVD: GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD) (clinicaltrials.gov) - P2 | N=110 | Recruiting | Sponsor: Chinese University of Hong Kong | Trial completion date: Dec 2026 ➔ Dec 2027 | Trial primary completion date: May 2026 ➔ May 2027

Trial completion date • Trial primary completion date

Exenatide-PD3: Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease (clinicaltrials.gov) - P3 | N=194 | Completed | Sponsor: University College, London | Active, not recruiting ➔ Completed

Trial completion • CNS Disorders • Movement Disorders • Parkinson's Disease

Exenatide for Smoking Cessation and Prevention of Weight Gain (clinicaltrials.gov) - P2 | N=140 | Completed | Sponsor: The University of Texas Health Science Center, Houston | Active, not recruiting ➔ Completed

Trial completion • Tobacco Cessation

Association of inflammation with glycemic control, insulin sensitivity, and beta-cell function in diabetic cats. (PubMed, J Vet Intern Med) - "Our data suggest that inflammatory state does not predict poor GC assessed by serum fructosamine concentration in diabetic cats, but BCF is an important determinant of GC."

Biomarker • Journal • Retrospective data • Diabetes • Inflammation • Metabolic Disorders • HP

EXCEED: A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs (clinicaltrials.gov) - P=N/A | N=24000 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Mar 2026 ➔ Oct 2026 | Trial primary completion date: Mar 2026 ➔ Oct 2026

Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Oncology • Pancreatic Cancer • Solid Tumor • Type 2 Diabetes Mellitus

Exenatide for Smoking Cessation and Prevention of Weight Gain (clinicaltrials.gov) - P2 | N=140 | Active, not recruiting | Sponsor: The University of Texas Health Science Center, Houston | Recruiting ➔ Active, not recruiting | N=216 ➔ 140 | Trial completion date: May 2026 ➔ Jan 2026 | Trial primary completion date: Mar 2026 ➔ Nov 2025

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Tobacco Cessation

BASIC2: Brain Activation and Satiety in Children 2 (clinicaltrials.gov) - P3 | N=63 | Active, not recruiting | Sponsor: Seattle Children's Hospital | Trial primary completion date: Feb 2025 ➔ Aug 2025

Trial primary completion date • Genetic Disorders • Obesity

Glucagon-Like Peptide-1 Receptor Agonists in Plastic Surgery: Perioperative Considerations and Safety Protocols. (PubMed, Cureus) - "Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed among plastic surgery patients for obesity and overweight...We reviewed each agent along with the administration route, half-life, average weight loss, and recommended discontinuation prior to surgery: dulaglutide: weekly injection, half-life of approximately five days, weight loss of 3%-5%, and discontinuation at >1 week before surgery; liraglutide: daily injection, half-life of approximately 13 hours, weight loss of 5%-7%, gastrointestinal (GI) adverse events up to 40%, and discontinuation at 24-48 hours before surgery; semaglutide (weekly): Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide Extended Release (ER) in Subjects With Type 2 Diabetes (SUSTAIN-3) showing superior glycated hemoglobin (HbA1c) reduction and weight loss compared with exenatide, GI adverse events including nausea (22%), diarrhea (11%), and vomiting (7%), and discontinuation at >1 week..."

Journal • Review • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Psychiatry • Suicidal Ideation • Type 2 Diabetes Mellitus

Formulation and characterization of exenatide-loaded PLGA microspheres prepared by coacervation. (PubMed, Drug Deliv Transl Res) - "Bydureon® is a once-weekly injection of poly(lactide-co-glycolide) (PLGA) microspheres containing exenatide acetate, a synthetic analog of the GLP-1 receptor agonist exendin-4. The framework of conditions and their effects on the formulations was established for loading exenatide in PLGA microspheres with desirable release characteristics. These results are useful for both microencapsulation of generic and new peptides in PLGA microspheres by coacervation."

Journal

Estimating the risk of cardiovascular outcomes and all-cause mortality in individuals with type 2 diabetes: Validation of the UKPDS outcomes model using TECOS and EXSCEL data. (PubMed, Diabetes Obes Metab) - "UKPDS-OM2 accurately simulated relative risks between randomized groups in both trials. The proportion of participants with the primary outcome was accurately estimated in both TECOS arms but underestimated by around one-third in both EXSCEL arms."

Journal • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Diabetes • Heart Failure • Metabolic Disorders • Myocardial Infarction • Ophthalmology • Renal Disease • Type 2 Diabetes Mellitus

Exenatide For Reducing the Reinforcing Effects of Cocaine (clinicaltrials.gov) - P1 | N=0 | Withdrawn | Sponsor: Christopher D. Verrico | N=44 ➔ 0 | Recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal

Peripheral insulin resistance may predict exenatide treatment response in Parkinson's disease (MDS Congress 2025) - " We performed a phase 3 trial of exenatide once weeklyover 96 weeks in non-diabetic patients with PD (ExPD3). Exenatide did not influence PD progression in the overall ExPD3 trial cohort. In ExPD2, there were a larger number of IR+ patients included, which may explain why exenatide was found to have positive effects overall. Although a non-significant trend towards potential benefit was noted in the small subgroup ofIR+ patients in ExPD3, the hypothesis that IR underpins responsiveness to exenatide would require further trial evaluation of a centrally penetrant GLP1 agonist in PD enriching for IR to formally evaluate this possibility."

CNS Disorders • Movement Disorders • Parkinson's Disease • CRP

LIBERATE-1: Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Vivani Medical, Inc | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Incretin Hormones GLP-1 and GIP Normalize Energy Utilization and Reduce Inflammation in the Brain in Alzheimer's Disease and Parkinson's Disease: From Repurposed GLP-1 Receptor Agonists to Novel Dual GLP-1/GIP Receptor Agonists as Potential Disease-Modifying Therapies. (PubMed, CNS Drugs) - "A phase II study testing liraglutide in patients with AD showed first improvements, and two phase II trials testing exendin-4 (exenatide, Bydureon®) or lixisenatide showed improvements in patients with PD...Semaglutide (Rybelsus®; Wegovy®; Ozempic®) is currently in two phase III trials for AD...Newer dual GLP-1/GIP receptor agonists have been developed that can more easily cross the BBB and that show improved protection in animal models of AD and PD. Therefore, GLP-1 and GIP receptor agonists that can cross the BBB show promise as treatments for chronic neurodegenerative disorders."

Journal • Alzheimer's Disease • CNS Disorders • Inflammation • Movement Disorders • Parkinson's Disease • IGF1

Impact of changes in conventional risk factors induced by once-weekly GLP-1 receptor agonist exenatide on cardiovascular outcomes: an EXSCEL post hoc analysis. (PubMed, Cardiovasc Diabetol) - "These model simulations explain only a modest proportion of the impact of observed EQW-induced changes in conventional CV risk factors on EXSCEL outcomes, apart from hHF and MI. Up to 1-year changes in conventional risk factors did not mediate the observed ACM risk reduction."

Biomarker • Clinical • Journal • Retrospective data • Cardiovascular • Congestive Heart Failure • Diabetes • Dyslipidemia • Heart Failure • Metabolic Disorders • Myocardial Infarction • Type 2 Diabetes Mellitus

Exenatide Once Weekly in the Treatment of Patients with Multiple System Atrophy. (PubMed, Ann Neurol) - "Exenatide was associated with positive effects on participant-reported symptoms and clinician-rated MSA severity. In contrast, none of the objective comparisons differed according to randomization. Given the open label trial design, the discrepancy between the primary outcome and the objective measures may be explicable as placebo effects/observer bias. ANN NEUROL 2025."

Journal • CNS Disorders • Movement Disorders • Multiple System Atrophy • NEFL

A Case Series on the Efficacy of the Pharmacological Treatment of Lipedema: The Italian Experience with Exenatide. (PubMed, Clin Pract) - " Five different cases of women with lipedema and insulin resistance, treated with Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) and once-weekly exenatide, in association or not with lifestyle changes (diet or physical activity) for 3 to 6 months are described. The improvement in symptoms and clinical signs of lipedema, in addition to the reduction in adipose tissue in patients with lipedema and insulin resistance with exenatide, suggests a novel pharmacological approach to the disease, which can be combined with other conservative and surgical treatments to promote weight reduction. These results also highlight the association of this disease with metabolic alterations and the fundamental role of an accurate diagnosis followed by the treatment of comorbidities and excess weight in these patients."

Journal • Aesthetic Medicine • Endocrine Disorders • Genetic Disorders • Inflammation • Obesity • Pain

Effect of the GLP-1 receptor agonist exenatide on pro-inflammatory and metabolic biomarkers in individuals with alcohol use disorder: Post hoc results from a randomized, double-blinded, placebo-controlled clinical trial. (PubMed, Alcohol Clin Exp Res (Hoboken)) - "Our findings support the well-established link between AUD and inflammation. However, treatment with the GLP-1 receptor agonist exenatide did not impact pro-inflammatory and metabolic biomarkers."

Biomarker • Clinical • Journal • Retrospective data • Addiction (Opioid and Alcohol) • Dyslipidemia • Metabolic Disorders • Oncology • CCL2 • CRP • CXCL8 • FGF21 • IFNG • IL10 • IL13 • IL2 • IL4 • IL6 • LEP • PPY • TNFA

Utilization of Proteomic Measures for Early Detection of Drug Benefits and Adverse Effects. (PubMed, J Clin Pharmacol) - "Using four clinical trials representing a diverse set of diseases and drug classes (EXSCEL: exenatide/GLP-1 RA, SUGAR-DM-HF: empagliflozin/SGLT2i, PRADA: epirubicin/anthracycline, and AMPLE: abatacept/immunomodulator and adalimumab/TNF inhibitor), we hypothesized that previously validated proteomic measures for cardiometabolic outcomes could enable the detection of beneficial and adverse drug effects in fewer participants over a shorter follow-up period. Changes in SomaSignalTM proteomic tests over time in response to treatment were assessed in the EXSCEL (baseline vs 1 year; once-weekly exenatide (EQW) (n) = 1812 vs control (n) = 1787), SUGAR-DM-HF (baseline vs 12 weeks and 36 weeks; empagliflozin (n) = 45 vs control (n) = 52), AMPLE (baseline vs 85 days and 1 year; abatacept (n) = 210, adalimumab (n) = 222), and PRADA (baseline vs 7-10 days and 3 months, n = 120) trial...In contrast, anthracycline treatment led to significant increases in heart failure mortality risk..."

Adverse events • Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Exenatide Once-weekly as a Treatment for Multiple System Atrophy (clinicaltrials.gov) - P2 | N=50 | Completed | Sponsor: University College, London | Recruiting ➔ Completed

Trial completion • CNS Disorders • Movement Disorders • Multiple System Atrophy

Discontinuation Rates of Once-Weekly GLP-1 Receptor Agonists (GLP-1 RAs) in Patients With Type 2 Diabetes (ISPOR 2025) - "The median time to treatment discontinuation was 327 days for tirzepatide, 240 days for semaglutide, 214 days for dulaglutide, and 153 days for long-acting exenatide... This is among the few studies that assessed discontinuation of once-weekly GLP-1 RAs in patients with T2D. Among once-weekly GLP-1 RA products, tirzepatide had the lowest discontinuation rate."

Clinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

BASIC2: Brain Activation and Satiety in Children 2 (clinicaltrials.gov) - P3 | N=63 | Active, not recruiting | Sponsor: Seattle Children's Hospital | Trial completion date: May 2025 ➔ Feb 2026

Trial completion date • Genetic Disorders • Obesity

DUAL GLP-1/GIP RECEPTOR AGONISTS THAT CAN CROSS THE BBB SHOW SUPERIOR NEUROPROTECTIVE EFFECTS (ADPD 2025) - "Methods Bydureon (exenatide) and Adlyxin (lixisenatide) showed disease-modifying protective effects in patients with PD in two phase 2 clinical trials...NLY01, a pegylated form of exenatide that can't cross the BBB did not show any effects in PD patients in a phase 2 trial...Results Currently, two phase 3 trials are ongoing, testing the diabetes drug Ozempic/Wegovy (semaglutide) in AD patients...In animal models of AD or PD, dual agonists were able to protect neurons better than GLP-1 class drugs such as liraglutide, semaglutide or tirzepatide that were designed to treat diabetes and that stay in the blood for longer periods. Conclusions The dual GLP-1/GIP receptor agonist KP405 (DA5-CH) is currently in a phase 1 clinical trial and Results will be shared at the conference."

Alzheimer's Disease • CNS Disorders • Diabetes • Inflammation • Metabolic Disorders • Movement Disorders • Parkinson's Disease